title: Pharmacokinetics of bevacizumab in haemodialysis.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Garnier-Viougeat
authors.forename: Olivier
authors.initials: O
authors.lastname: Rixe
authors.forename: Gilles
authors.initials: G
authors.lastname: Paintaud
authors.forename: David
authors.initials: D
authors.lastname: Ternant
authors.forename: Danielle
authors.initials: D
authors.lastname: Degenne
authors.forename: Roger
authors.initials: R
authors.lastname: Mouawad
authors.forename: Gilbert
authors.initials: G
authors.lastname: Deray
authors.forename: Hassane
authors.initials: H
authors.lastname: Izzedine
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015314:Dialysis Solutions / Q000737:chemistry*; D029721:Drosophila Proteins; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D011956:Receptors, Cell Surface; D006435:Renal Dialysis / Q000379:methods*; D051437:Renal Insufficiency / Q000378:metabolism* / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015314:Dialysis Solutions; D029721:Drosophila Proteins; D011956:Receptors, Cell Surface; D042461:Vascular Endothelial Growth Factor A; C405956:gustatory receptor, Drosophila; D000068258:Bevacizumab